{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:48:30Z","timestamp":1783050510047,"version":"3.54.6"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In response to the World Health Organization\u2019s advocacy for patient-centered care, Fujian Province, China, initiated the promotion of Digital Adherence Technology (DAT) in 2024 as an optional strategy to enhance treatment adherence\u2014a critical determinant of patient outcomes. This study aimed to evaluate the real-world implementation and effectiveness of this program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multi-site study in four prefecture-level cities where DAT had been deployed to over 100 patients. Data were extracted from the national Tuberculosis Information Management System and linked with DAT platform records. Patients with DAT records were assigned to the DAT group, others to the conventional care group. We analyzed factors associated with DAT non-adoption. Adherence was compared between groups using three indicators: sputum smear examination rate at month two, smear conversion rate at month two (among bacteriologically confirmed patients), and loss to follow-up rate. Propensity score matching (PSM) was employed to balance baseline characteristics, followed by subgroup analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall DAT utilization rate was 50.90%. Protective factors against DAT non-use included female sex (aOR\u202f=\u202f0.829, 95% CI: 0.716\u20130.960), non-Han ethnicity (aOR\u202f=\u202f0.555, 95% CI: 0.343\u20130.898), use of fixed-dose combination therapy (aOR\u202f=\u202f0.806, 95% CI: 0.666\u20130.975), and concurrent extrapulmonary TB (aOR\u202f=\u202f0.761, 95% CI: 0.642\u20130.902). Compared to Fuzhou, patients in Putian, Quanzhou, and Ningde had significantly lower odds of non-use (aORs: 0.024, 0.076, 0.030). Migrant status (aOR\u202f=\u202f2.621, 95% CI: 2.144\u20133.203) and symptomatic presentation at diagnosis (aOR\u202f=\u202f1.604, 95% CI: 1.401\u20131.836) were risk factors. The DAT group demonstrated a significantly higher month-two smear examination rate than the conventional group in both the full and PSM-matched cohorts (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). No significant inter-group differences were found in month-two smear conversion rates or loss to follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DAT utilization in Fujian remains moderate and is influenced by specific demographic and clinical factors. While DAT can improve process adherence indicators, its impact on definitive treatment outcomes requires further investigation. Optimization of patient management should include formal integration of DAT, workflow streamlining, and personalized intervention strategies. Future research must develop and evaluate effective interventions for DAT-identified non-adherent patients to translate monitoring data into improved clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1759922","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:34:40Z","timestamp":1768545280000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of the utilization and effectiveness of tuberculosis digital adherence technology in southeastern China"],"prefix":"10.3389","volume":"14","author":[{"given":"Daiquan","family":"Chen","sequence":"first","affiliation":[{"name":"Fujian Center for Disease Control and Prevention","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisong","family":"Dai","sequence":"additional","affiliation":[{"name":"Fujian Center for Disease Control and Prevention","place":["Fuzhou, Fujian, China"]},{"name":"Fujian Provincial Key Laboratory of Zoonosis Research","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Lin","sequence":"additional","affiliation":[{"name":"Fujian Center for Disease Control and Prevention","place":["Fuzhou, Fujian, China"]},{"name":"Fujian Provincial Key Laboratory of Zoonosis Research","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhen","family":"Wei","sequence":"additional","affiliation":[{"name":"Fujian Center for Disease Control and Prevention","place":["Fuzhou, Fujian, China"]},{"name":"Fujian Provincial Key Laboratory of Zoonosis Research","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian Center for Disease Control and Prevention","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqin","family":"Deng","sequence":"additional","affiliation":[{"name":"Fujian Center for Disease Control and Prevention","place":["Fuzhou, Fujian, China"]},{"name":"Fujian Provincial Key Laboratory of Zoonosis Research","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref1","volume-title":"Global tuberculosis report 2025","year":"2025"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.5588\/ijtld.19.0754","article-title":"Clinical and economic impact of medication non-adherence in drug-susceptible tuberculosis: a systematic review","volume":"24","author":"Chimeh","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/S2214-109X(23)00068-2","article-title":"Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial","volume":"11","author":"Liu","year":"2023","journal-title":"Lancet Glob Health"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.5588\/ijtld.12.0080","article-title":"Implementation and community involvement in DOTS strategy: a systematic review of studies in China","volume":"16","author":"Hou","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref5","volume-title":"WHO consolidated guidelines on tuberculosis: Module 4: treatment and care","year":"2025"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(23)02270-5","article-title":"Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial","volume":"403","author":"Wei","year":"2024","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0140-6736(18)32993-3","article-title":"Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial","volume":"393","author":"Story","year":"2019","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"102745","DOI":"10.1016\/j.eclinm.2024.102745","article-title":"Treatment adherence and clinical outcomes amongst in people with drug-susceptible tuberculosis using medication monitor and differentiated care approach compared with standard of care in South Africa: a cluster randomized trial","volume":"75","author":"Charalambous","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12916-022-02521-y","article-title":"Effectiveness of a digital medication event reminder and monitor device for patients with tuberculosis (SELFTB): a multicenter randomized controlled trial","volume":"20","author":"Manyazewal","year":"2022","journal-title":"BMC Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e2144210","DOI":"10.1001\/jamanetworkopen.2021.44210","article-title":"In-person vs electronic directly observed therapy for tuberculosis treatment adherence: a randomized noninferiority trial","volume":"5","author":"Burzynski","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(24)02847-2","article-title":"Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials","volume":"405","author":"Jerene","year":"2025","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e016997","DOI":"10.1136\/BMJGH-2024-016997","article-title":"Modelling the epidemiological and economic impact of digital adherence technologies with differentiated care for tuberculosis treatment in Ethiopia","volume":"9","author":"Gosc\u00e9","year":"2024","journal-title":"BMJ Glob Health"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2024-015654","article-title":"Cost and cost-effectiveness of digital technologies for support of tuberculosis treatment adherence: a systematic review","volume":"9","author":"Kafie","year":"2024","journal-title":"BMJ Glob Health"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e0232337","DOI":"10.1371\/journal.pone.0232337","article-title":"Electronic medication monitor for people with tuberculosis: implementation experience from thirty counties in China","volume":"15","author":"Wang","year":"2020","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e0000322","DOI":"10.1371\/journal.pdig.0000322","article-title":"Acceptability and feasibility of digital adherence technologies for drug-susceptible tuberculosis treatment supervision: a meta-analysis of implementation feedback","volume":"2","author":"Guzman","year":"2023","journal-title":"PLOS Digit Health"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e0000138","DOI":"10.1371\/journal.pdig.0000138","article-title":"Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda","volume":"2","author":"Kiwanuka","year":"2023","journal-title":"PLOS Digit Health"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1111\/jan.15810","article-title":"Digitizing nursing: a theoretical and holistic exploration to understand the adoption and use of digital technologies by nurses","volume":"79","author":"Wynn","year":"2023","journal-title":"J Adv Nurs"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/S1473-3099(24)00587-5","article-title":"Barriers and facilitators to the implementation of electronic monitors to improve adherence and health outcomes in patients with tuberculosis: a systematic review","volume":"25","author":"Li","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1371\/journal.pmed.0040238","article-title":"Patient adherence to tuberculosis treatment: a systematic review of qualitative research","volume":"4","author":"Munro","year":"2007","journal-title":"PLoS Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.19982\/j.issn.1000-6621.20250237","article-title":"Analysis of the factors influencing adherence and treatment outcomes among pulmonary tuberculosis patients with comorbidities in China from 2010 to 2023","volume":"47","author":"Yan","year":"2025","journal-title":"Chin J Antituberc"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.16506\/j.1009-6639.2024.09.013","article-title":"Analysis of treatment outcome and influencing factors among students with pulmonary tuberculosis in Guizhou Province from 2012 to 2021","volume":"25","author":"Li","year":"2024","journal-title":"Chin Prev Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/pharmaceutics16020178","article-title":"Fixed-dose combination formulations in solid Oral drug therapy: advantages, limitations, and design features","volume":"16","author":"Wilkins","year":"2024","journal-title":"Pharmaceutics"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1039\/c7ra11820a","article-title":"Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in Xinjiang, China: a prospective study","volume":"8","author":"Gong","year":"2018","journal-title":"RSC Adv"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s12879-023-08395-6","article-title":"Prevalence and factors associated with sputum smear non-conversion after two months of tuberculosis treatment among smear-positive pulmonary tuberculosis patients in Rwanda: a cross-sectional study","volume":"23","author":"Gatete","year":"2023","journal-title":"BMC Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12890-021-01483-w","article-title":"Sputum smear conversion and associated factors among smear-positive pulmonary tuberculosis patients in east Gojjam zone, Northwest Ethiopia: a longitudinal study","volume":"21","author":"Asemahagn","year":"2021","journal-title":"BMC Pulm Med"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1759922\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:35:17Z","timestamp":1771918517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1759922\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":25,"alternative-id":["10.3389\/fpubh.2026.1759922"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1759922","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1759922"}}